Target INR Range for Antiphospholipid Syndrome

Evidence-Based Recommendation

The American Heart Association/American Stroke Association recommends targeting an INR of 2.0 to 3.0 (moderate intensity) for patients with antiphospholipid syndrome on warfarin therapy, as it effectively balances the risk of excessive bleeding against the risk of thrombosis, with a Class 2a recommendation (Level B-R evidence) 1, 2
The American Heart Association/American Stroke Association provides a recommendation that it is reasonable to choose a target INR between 2.0 and 3.0 over a target INR >3.0 for patients with confirmed antiphospholipid syndrome, to balance the risk of bleeding and thrombosis 1, 2

For patients with antiphospholipid syndrome who have had venous thrombotic events, the standard INR 2.0-3.0 target is recommended 1
For patients with arterial thrombosis in antiphospholipid syndrome, including stroke or transient ischemic attack, the American Heart Association/American Stroke Association recommends a moderate-intensity target (INR 2.0-3.0) rather than higher intensity 1, 2
For high-risk patients with lupus anticoagulant, anticardiolipin, and anti-β2 glycoprotein-I antibodies, the target INR remains 2.0-3.0 1

The American Heart Association/American Stroke Association gives a Class 3 (Harm) recommendation against using rivaroxaban or other direct oral anticoagulants in triple-positive antiphospholipid syndrome patients with a history of thrombosis, as it is associated with excess thrombotic events compared to warfarin 1, 2

Standard INR monitoring frequency applies, with more frequent monitoring initially until stable, then extending to every 4-12 weeks once consistently therapeutic, according to Praxis Medical Insights 3